SCHEMBL19391

SCHEMBL19391

O=C1Cc2cc(O)ccc2N1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 4/20 0.67
PDE3B Q13370 1/20 0.54
PDE3A Q14432 1/20 0.54
PGR P06401 2/20 0.54
PDK2 Q15119 1/20 0.53
MAOB P27338 3/20 0.53
MAOA P21397 1/20 0.53
CMA1 P23946 2/20 0.52
EPHX2 P34913 1/20 0.51
GAA P10253 2/20 0.51
GRIA1 P42261 2/20 0.50
CACNG8 Q8WXS5 2/20 0.50
TDP2 O95551 1/20 0.49
CYP1A2 P05177 1/20 0.47
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
EIF2AK2 P19525 1/20 0.46
DRD2 P14416 1/20 0.46
DRD4 P21917 1/20 0.46
SMYD3 Q9H7B4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methane SCHEMBL9732811 0.98 AHR (0.65) AHRPDE3BPDE3APGRPDK2
SCHEMBL31478025 0.84 AHR (0.61) AHRPDE3BPDE3APDK2MAOB
SCHEMBL1833499 0.84 AHR (0.61) AHRPDE3BPDE3APDK2MAOB
SCHEMBL426336 0.82 NPC1 (0.55) AHRPDE3BPDE3AMAOBMAOA
SCHEMBL26768740 0.82 TDP2 (0.51) AHRPDK2MAOBMAOACMA1
SCHEMBL29853427 0.82 TDP2 (0.51) AHRPDK2MAOBMAOACMA1
SCHEMBL31734649 0.82 MAOA (0.55) AHRPDE3BPDE3APDK2MAOB
SCHEMBL5639130 0.81 AHR (0.50) AHRPDE3BPDE3APGRPDK2
SCHEMBL154614 0.80 AHR (1.00) AHRPDE3BPDE3APGRPDK2
SCHEMBL6405990 0.79 MAPT (0.58) AHRMAOBMAOADRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116585307-B Application of 5-hydroxy oxindole in preparation of medicines for treating acute respiratory distress syndrome 重庆医科大学 2024-08-20 CN claimed
CN-116585307-A Application of 5-hydroxy oxindole in preparation of medicines for treating acute respiratory distress syndrome 重庆医科大学 2023-08-15 CN claimed
CN-111208230-B Method for detecting American cockroach intestinal flora metabolite 天津中医药大学 2022-02-25 CN claimed
US-20220016099-A1 BENZIMIDAZOLE OR BENZOXAZOLE DERIVATIVES FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASE, DIABETES, AND COMPLICATIONS THEREOF TRINUERO (KR) 2022-01-20 US claimed
CN-109942480-B Synthetic method of aromatic ring indole-5-alcohol compound 河南师范大学 2021-09-10 CN claimed
WO-2020116742-A1 BENZIMIDAZOLE OR BENZOXAZOLE DERIVATIVES FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASE, DIABETES, AND COMPLICATIONS THEREOF 주식회사 트리뉴로 2020-06-11 WO claimed
CN-111208230-A Method for detecting American cockroach intestinal flora metabolite 天津中医药大学 2020-05-29 CN claimed
WO-2001078722-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING 5-HYDROXYOXINDOLE AND USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2001-10-25 WO claimed
EP-4720316-A2 NON-VIRAL CELL ENGINEERING Arsenal Biosciences, Inc. (US) 2026-04-08 EP disclosed
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 EP disclosed
WO-2025097170-A1 A METHOD OF MINIMIZING OR ELIMINATING NEPHROTOXICITY IN PATIENTS UNDERGOING TREATMENT WITH ANTIMICROBIAL OR ANTICANCER DRUGS PROLETARIAT THERAPEUTICS, INC. (US) 2025-05-08 WO disclosed
WO-2025093926-A1 A METHOD OF MINIMIZING OR ELIMINATING NEPHROTOXICITY IN PATIENTS UNDERGOING CISPLATIN-BASED CHEMOTHERAPY VIA SEQUENTIAL ADMINISTRATION OF A PROTECTIVE AGENT FOLLOWED BY A TOXIC AGENT AKIHIKO SAITO (JP) 2025-05-08 WO disclosed
WO-2025064829-A1 A MOLECULAR SCAFFOLD FOR DEPLETING HRPN13 AND A SELECT GROUP OF KEN BOX PROTEINS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-03-27 WO disclosed
WO-2024259376-A2 NON-VIRAL CELL ENGINEERING ARSENAL BIOSCIENCES, INC. (US) 2024-12-19 WO disclosed
US-4629733-A CARDIOVASCULAR DISORDERS DR. KARL THOMAE GMBH (DE) 1986-12-16 US disclosed
EP-0170117-A1 Oxindole derivatives, process for their preparation, pharmaceutical compositions containing them and intermediate compounds Roche Diagnostics GmbH (DE) 1986-02-05 EP disclosed
EP-0026474-B1 COMPOSITION AND PROCESS FOR OXIDATIVE DYEING OF HAIR Wella Aktiengesellschaft (DE) 1983-06-08 EP disclosed
EP-0003771-B1 CARBOSTYRILE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dr. Karl Thomae GmbH (DE) 1982-10-20 EP disclosed
US-4329347-A Cardiotonic and antithrombotic sulfur-containing derivatives of carbostyril BOEHRINGER INGELHEIM GMBH (DE) 1982-05-11 US disclosed
EP-0003771-A1 Carbostyrile derivatives, their preparation and pharmaceutical compositions containing them Dr. Karl Thomae GmbH (DE) 1979-09-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220016099-A1 BENZIMIDAZOLE OR BENZOXAZOLE DERIVATIVES FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASE, DIABETES, AND COMPLICATIONS THEREOF KEAP1, SLC5A1, GCLC AHR 1552/4885PDE3B 1882/4885PDE3A 2288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.